Company
Wayshine Biopharm, Inc.
Wayshine Biopharm, Inc. has 2 drugs tracked on RxWires: 1 in Phase 2, 1 in Phase 1/2.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| WSD0922-FU Tablets, Dose level A | Phase 2 | Non Small Cell Lung Cancer |
| Osimertinib (Tagrisso®) | Phase 1/2 | Non Small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow Wayshine Biopharm, Inc. on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.